相关实验视频
Updated: Jul 8, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
在与华法林相关的内出血中,给予前红素复合缩剂的时间
Brock Townsend1, Joe Slechta1, Brian W Gilbert1
1Pharmacy department, Wesley Medical Center, 550 N Hillside St, Wichita, KS 67214, United States of America.
The American journal of emergency medicine
|December 10, 2023
概括
针对与华法林相关的内出血 (ICH) 快速服用4因子前列红素缩物 (4F-PCC) 并没有显著影响血静的实现. 这项研究没有发现4F-PCC时间和血液瘤扩张率之间的关联.
科学领域:
- 神经学 神经学
- 血液学 血液学 血液学
- 紧急医疗 紧急医疗
背景情况:
- 目前的指导方针主张在华法林相关的内出血 (ICH) 中快速逆转抗凝剂.
- 然而,逆转剂的具体时间目标及其对血液瘤扩张的影响尚未明确.
- 有限的研究存在于ICH患者的逆转时间和结果之间的关联.
研究的目的:
- 评估4因子前血缩剂 (4F-PCC) 给药时间和在华法林相关的ICH中实现有效的静血之间的关联.
- 为了确定4F-PCC的使用时间是否会影响ICH患者的血液瘤扩张率.
- 评估4F-PCC的时间对关键临床结果的影响.
主要方法:
- 回顾性,观察性,单中心研究.
- 华法林相关性ICH患者根据CT诊断到4F-PCC给药的时间分为三组:<45分钟,45-90分钟和>90分钟.
- 主要结局:有效血静率,定义为≤20%的血体积增加.
主要成果:
- 总共有39名患者被纳入分析.
- 在三个基于时间的组 (85.7% vs. 73.3% vs. 90%,p=0.514) 中,没有观察到主要结局 (有效静血) 的显著差异.
- 二次性结局,包括住院死亡率和住院时间 (LOS),也显示,两组之间没有显著差异.
结论:
- 在与华法林相关的ICH患者中,四因子前列红素缩剂 (4F-PCC) 给药的时间与实现有效的血静无关.
- 血液瘤扩张率在4F-PCC的不同时间间隔中是相似的.
- 这些发现表明,在这种患者群体中,立即服用可能对血液静止不至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Coagulation
6.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.8K
Extrinsic and Intrinsic Pathways of Hemostasis
7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K
Introduction to Hemostasis
8.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.0K
Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Disorders of Hemostasis
922
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
922

